These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 18414390)

  • 1. Chronic heart rate reduction by ivabradine prevents endothelial dysfunction in dyslipidaemic mice.
    Drouin A; Gendron ME; Thorin E; Gillis MA; Mahlberg-Gaudin F; Tardif JC
    Br J Pharmacol; 2008 Jun; 154(4):749-57. PubMed ID: 18414390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heart rate-associated mechanical stress impairs carotid but not cerebral artery compliance in dyslipidemic atherosclerotic mice.
    Bolduc V; Drouin A; Gillis MA; Duquette N; Thorin-Trescases N; Frayne-Robillard I; Des Rosiers C; Tardif JC; Thorin E
    Am J Physiol Heart Circ Physiol; 2011 Nov; 301(5):H2081-92. PubMed ID: 21926346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Defying the economists: a decrease in heart rate improves not only cardiac but also endothelial function.
    Triggle CR
    Br J Pharmacol; 2008 Jun; 154(4):727-8. PubMed ID: 18438420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heart rate reduction with ivabradine improves erectile dysfunction in parallel to decrease in atherosclerotic plaque load in ApoE-knockout mice.
    Baumhäkel M; Custodis F; Schlimmer N; Laufs U; Böhm M
    Atherosclerosis; 2010 Sep; 212(1):55-62. PubMed ID: 20347444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heart rate reduction by ivabradine reduces oxidative stress, improves endothelial function, and prevents atherosclerosis in apolipoprotein E-deficient mice.
    Custodis F; Baumhäkel M; Schlimmer N; List F; Gensch C; Böhm M; Laufs U
    Circulation; 2008 May; 117(18):2377-87. PubMed ID: 18443241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ROS-sensitive cytochrome P450 activity maintains endothelial dilatation in ageing but is transitory in dyslipidaemic mice.
    Krummen S; Drouin A; Gendron ME; Falck JR; Thorin E
    Br J Pharmacol; 2006 Apr; 147(8):897-904. PubMed ID: 16474414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heart Rate reduction by IVabradine for improvement of ENDothELial function in patients with coronary artery disease: the RIVENDEL study.
    Mangiacapra F; Colaiori I; Ricottini E; Balducci F; Creta A; Demartini C; Minotti G; Di Sciascio G
    Clin Res Cardiol; 2017 Jan; 106(1):69-75. PubMed ID: 27520989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heart rate lowering by specific and selective I(f) current inhibition with ivabradine: a new therapeutic perspective in cardiovascular disease.
    DiFrancesco D; Camm JA
    Drugs; 2004; 64(16):1757-65. PubMed ID: 15301560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two distinct pathways account for EDHF-dependent dilatation in the gracilis artery of dyslipidaemic hApoB+/+ mice.
    Krummen S; Falck JR; Thorin E
    Br J Pharmacol; 2005 May; 145(2):264-70. PubMed ID: 15765099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ivabradine: in adults with chronic heart failure with reduced left ventricular ejection fraction.
    Perry CM
    Am J Cardiovasc Drugs; 2012 Dec; 12(6):415-26. PubMed ID: 23181944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heart rate contributes to the vascular effects of chronic mental stress: effects on endothelial function and ischemic brain injury in mice.
    Custodis F; Gertz K; Balkaya M; Prinz V; Mathar I; Stamm C; Kronenberg G; Kazakov A; Freichel M; Böhm M; Endres M; Laufs U
    Stroke; 2011 Jun; 42(6):1742-9. PubMed ID: 21527760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reversing dobutamine-induced tachycardia using ivabradine increases stroke volume with neutral effect on cardiac energetics in left ventricular post-ischaemia dysfunction.
    Bakkehaug JP; Naesheim T; Torgersen Engstad E; Kildal AB; Myrmel T; How OJ
    Acta Physiol (Oxf); 2016 Oct; 218(2):78-88. PubMed ID: 27145482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Catechin treatment improves cerebrovascular flow-mediated dilation and learning abilities in atherosclerotic mice.
    Drouin A; Bolduc V; Thorin-Trescases N; Bélanger É; Fernandes P; Baraghis E; Lesage F; Gillis MA; Villeneuve L; Hamel E; Ferland G; Thorin E
    Am J Physiol Heart Circ Physiol; 2011 Mar; 300(3):H1032-43. PubMed ID: 21186270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heart rate reduction by pharmacological If current inhibition.
    Cargnoni A; Ceconi C; Stavroula G; Ferrari R
    Adv Cardiol; 2006; 43():31-44. PubMed ID: 16936470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical results with I(f) current inhibition by ivabradine.
    Berdeaux A
    Drugs; 2007; 67 Suppl 2():25-33. PubMed ID: 17999561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Ivabradine on Central Aortic Blood Pressure and Myocardial Perfusion in Patients With Stable Coronary Artery Disease.
    Dillinger JG; Maher V; Vitale C; Henry P; Logeart D; Manzo Silberman S; Allée G; Levy BI
    Hypertension; 2015 Dec; 66(6):1138-44. PubMed ID: 26418022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Ivabradine on Endothelial Function in Patients with Stable Angina Pectoris: Assessment with the Endo-PAT 2000 Device.
    Jedlickova L; Merkovska L; Jackova L; Janicko M; Fedacko J; Novakova B; Chmelarova A; Majernik J; Pella D
    Adv Ther; 2015 Oct; 32(10):962-70. PubMed ID: 26525390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial.
    Fox K; Ford I; Steg PG; Tendera M; Ferrari R;
    Lancet; 2008 Sep; 372(9641):807-16. PubMed ID: 18757088
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heart-rate reduction by If-channel inhibition with ivabradine restores collateral artery growth in hypercholesterolemic atherosclerosis.
    Schirmer SH; Degen A; Baumhäkel M; Custodis F; Schuh L; Kohlhaas M; Friedrich E; Bahlmann F; Kappl R; Maack C; Böhm M; Laufs U
    Eur Heart J; 2012 May; 33(10):1223-31. PubMed ID: 21821843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential effects of heart rate reduction with ivabradine in two models of endothelial dysfunction and oxidative stress.
    Kröller-Schön S; Schulz E; Wenzel P; Kleschyov AL; Hortmann M; Torzewski M; Oelze M; Renné T; Daiber A; Münzel T
    Basic Res Cardiol; 2011 Nov; 106(6):1147-58. PubMed ID: 21964558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.